Tanke Biosciences Corp Financials

TNBI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2013 Currency USD FYE December

This page shows Tanke Biosciences Corp (TNBI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2012 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Tanke Biosciences Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Tanke Biosciences Corp has an operating margin of 15.9%, meaning the company retains $16 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is up from 7.3% the prior year.

Growth

Tanke Biosciences Corp's revenue surged 19.8% year-over-year to $28.6M, reflecting rapid business expansion. This strong growth earns a score of 65/100.

Leverage

100

Tanke Biosciences Corp carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Tanke Biosciences Corp's current ratio of 1.85 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Tanke Biosciences Corp generated -$1.2M in operating cash flow, capex of $856K consumed most of it, leaving -$2.0M in free cash flow. This results in a low score of 36/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Tanke Biosciences Corp generates a -1.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is up from -19.8% the prior year.

Altman Z-Score Grey Zone

2.12

Tanke Biosciences Corp scores 2.12, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Weak

3/9

Tanke Biosciences Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

5.63x

For every $1 of reported earnings, Tanke Biosciences Corp generates $5.63 in operating cash flow (-$1.2M OCF vs -$210K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Adequate

3.1x

Tanke Biosciences Corp earns $3.1 in operating income for every $1 of interest expense ($4.5M vs $1.4M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$28.6M

YoY+19.8%

Tanke Biosciences Corp generated $28.6M in revenue in fiscal year 2012. This represents an increase of 19.8% from the prior year.

EBITDA

$5.2M

YoY+141.6%

Tanke Biosciences Corp's EBITDA was $5.2M in fiscal year 2012, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 141.6% from the prior year.

Net Income

-$210K

YoY+93.3%

Tanke Biosciences Corp reported -$210K in net income in fiscal year 2012. This represents an increase of 93.3% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$2.0M

YoY-169.1%

Tanke Biosciences Corp generated -$2.0M in free cash flow in fiscal year 2012, representing cash available after capex. This represents a decrease of 169.1% from the prior year.

Cash & Debt

$6.2M

YoY-19.9%

Tanke Biosciences Corp held $6.2M in cash against $793K in long-term debt as of fiscal year 2012.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+0.0%

Tanke Biosciences Corp had 13M shares outstanding in fiscal year 2012. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

34.8%

YoY-2.0pp

Tanke Biosciences Corp's gross margin was 34.8% in fiscal year 2012, indicating the percentage of revenue retained after direct costs. This is down 2.0 percentage points from the prior year.

Operating Margin

15.9%

YoY+8.6pp

Tanke Biosciences Corp's operating margin was 15.9% in fiscal year 2012, reflecting core business profitability. This is up 8.6 percentage points from the prior year.

Net Margin

-0.7%

YoY+12.4pp

Tanke Biosciences Corp's net profit margin was -0.7% in fiscal year 2012, showing the share of revenue converted to profit. This is up 12.4 percentage points from the prior year.

Return on Equity

-1.3%

YoY+18.4pp

Tanke Biosciences Corp's ROE was -1.3% in fiscal year 2012, measuring profit generated per dollar of shareholder equity. This is up 18.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$291K

YoY+18.1%

Tanke Biosciences Corp invested $291K in research and development in fiscal year 2012. This represents an increase of 18.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$856K

YoY+22.2%

Tanke Biosciences Corp invested $856K in capex in fiscal year 2012, funding long-term assets and infrastructure. This represents an increase of 22.2% from the prior year.

TNBI Income Statement

Metric	FY12	FY11	FY10	FY09
Revenue	$28.6M+19.8%	$23.8M+18.6%	$20.1M	N/A
Cost of Revenue	$18.6M+23.6%	$15.1M+18.6%	$12.7M	N/A
Gross Profit	$9.9M+13.4%	$8.8M+18.5%	$7.4M	N/A
R&D Expenses	$291K+18.1%	$246K	N/A	N/A
SG&A Expenses	$2.6M-42.7%	$4.5M+437.5%	$835K	N/A
Operating Income	$4.5M+160.6%	$1.7M-60.2%	$4.4M	N/A
Interest Expense	$1.4M+6.2%	$1.4M+1258.1%	$100K	N/A
Income Tax	$832K+22.1%	$681K+17.0%	$582K	N/A
Net Income	-$210K+93.3%	-$3.1M-214.5%	$2.7M+6.0%	$2.6M
EPS (Diluted)	N/A	$-0.24-170.6%	$0.34	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Revenue	$6.0M+8.3%	$5.6M+19.7%	$4.7M-30.3%	$6.7M-32.5%	$9.9M+33.3%	$7.4M+63.7%	$4.5M-31.8%	$6.7M
Cost of Revenue	$4.3M+15.9%	$3.8M+25.4%	$3.0M-32.7%	$4.5M-31.7%	$6.5M+39.0%	$4.7M+58.8%	$3.0M-31.7%	$4.3M
Gross Profit	$1.7M-7.2%	$1.8M+9.4%	$1.7M-25.4%	$2.2M-34.1%	$3.4M+23.5%	$2.7M+72.7%	$1.6M-31.8%	$2.3M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.4M+36.2%	$997K+1.6%	$982K+26.4%	$776K+35.2%	$574K-15.6%	$680K+25.7%	$541K-12.2%	$616K
Operating Income	-$530K-454.3%	$150K+475.2%	-$40K-111.0%	$363K-83.4%	$2.2M+45.8%	$1.5M+206.5%	$489K-52.1%	$1.0M
Interest Expense	-$47K-218.3%	$39K-81.7%	$215K-44.5%	$387K+22.5%	$316K-14.2%	$369K-1.2%	$373K+375.0%	-$136K
Income Tax	-$27K-150.3%	$54K+66.7%	$32K-82.1%	$179K-19.6%	$223K-29.0%	$314K+168.6%	$117K-33.6%	$176K
Net Income	-$302K-355.6%	$118K+117.5%	-$676K+13.3%	-$780K-180.6%	$969K+255.6%	$272K+140.6%	-$671K-133.7%	$2.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	$0.07+250.0%	$0.02+140.0%	$-0.05	N/A

TNBI Balance Sheet

Metric	FY12	FY11	FY10	FY09
Total Assets	$28.8M+15.9%	$24.9M+87.6%	$13.3M	N/A
Current Assets	$22.4M+18.3%	$18.9M+146.5%	$7.7M	N/A
Cash & Equivalents	$6.2M-19.9%	$7.7M+246.5%	$2.2M+22.2%	$1.8M
Inventory	$1.4M+19.1%	$1.2M-12.3%	$1.4M	N/A
Accounts Receivable	$2.0M+3.6%	$1.9M+8.5%	$1.8M	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$12.9M+43.1%	$9.0M+208.0%	$2.9M	N/A
Current Liabilities	$12.1M+241.1%	$3.5M+47.4%	$2.4M	N/A
Long-Term Debt	$793K+26.1%	$628K+38.7%	$453K	N/A
Total Equity	$15.8M-0.6%	$15.9M+94.2%	$8.2M+26.8%	$6.4M
Retained Earnings	$2.5M-7.8%	$2.7M-53.8%	$5.8M	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Total Assets	$28.8M-2.2%	$29.5M+2.8%	$28.7M-0.7%	$28.8M0.0%	$28.8M+5.7%	$27.3M+11.6%	$24.5M-1.7%	$24.9M
Current Assets	$19.7M-10.1%	$21.9M+0.8%	$21.7M-2.8%	$22.4M+0.7%	$22.2M+7.5%	$20.7M+12.4%	$18.4M-2.9%	$18.9M
Cash & Equivalents	$5.1M+7.0%	$4.7M-15.4%	$5.6M-9.4%	$6.2M-44.1%	$11.0M+10.1%	$10.0M+31.4%	$7.6M-0.8%	$7.7M
Inventory	$1.6M-20.8%	$2.1M+49.1%	$1.4M-1.3%	$1.4M-13.6%	$1.6M+30.3%	$1.3M-7.6%	$1.4M+14.5%	$1.2M
Accounts Receivable	$2.8M+15.8%	$2.4M+29.2%	$1.8M-7.1%	$2.0M-12.7%	$2.3M+25.3%	$1.8M+5.5%	$1.7M-10.3%	$1.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.1M-3.6%	$13.6M+2.4%	$13.3M+2.7%	$12.9M+5.0%	$12.3M+5.9%	$11.6M+26.9%	$9.2M+1.4%	$9.0M
Current Liabilities	$12.2M-3.7%	$12.7M+7.7%	$11.8M-2.5%	$12.1M+8.4%	$11.2M+14.2%	$9.8M+10.8%	$8.8M+148.8%	$3.5M
Long-Term Debt	$733K-9.4%	$809K-43.6%	$1.4M+81.0%	$793K-16.4%	$948K-40.3%	$1.6M	$0-100.0%	$628K
Total Equity	$15.6M-1.0%	$15.7M+3.3%	$15.2M-3.5%	$15.8M-4.7%	$16.5M+5.5%	$15.7M+2.4%	$15.3M-3.5%	$15.9M
Retained Earnings	$1.6M-15.7%	$1.9M+6.5%	$1.8M-27.2%	$2.5M-23.9%	$3.3M+42.2%	$2.3M+13.5%	$2.0M-24.9%	$2.7M

TNBI Cash Flow Statement

Metric	FY12	FY11	FY10	FY09
Operating Cash Flow	-$1.2M-132.4%	$3.7M-16.7%	$4.4M	N/A
Capital Expenditures	$856K+22.2%	$701K+821.5%	$76K	N/A
Free Cash Flow	-$2.0M-169.1%	$3.0M-31.5%	$4.3M	N/A
Investing Cash Flow	-$1.5M+58.4%	-$3.7M-30.0%	-$2.8M	N/A
Financing Cash Flow	$1.1M-80.7%	$5.8M+576.4%	-$1.2M	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Operating Cash Flow	$1.6M+1297.6%	-$135K-33.0%	-$101K+98.0%	-$5.0M-423.0%	$1.6M-12.2%	$1.8M+247.6%	$509K-30.4%	$731K
Capital Expenditures	$1.1M+75.0%	$613K-17.8%	$746K+1221.8%	$56K-86.3%	$412K+111.4%	$195K+0.6%	$194K-13.7%	$224K
Free Cash Flow	$538K+171.9%	-$748K+11.7%	-$847K+83.3%	-$5.1M-544.4%	$1.1M-27.5%	$1.6M+399.4%	$315K-37.8%	$507K
Investing Cash Flow	-$1.1M-67.7%	-$645K+13.5%	-$746K-754.1%	$114K+128.9%	-$394K+54.5%	-$866K-127.9%	-$380K+82.0%	-$2.1M
Financing Cash Flow	-$241K-51.5%	-$159K-169.2%	$230K+204.8%	$76K+268.1%	-$45K-103.2%	$1.4M+558.1%	-$305K+34.7%	-$466K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TNBI Financial Ratios

Metric	FY12	FY11	FY10	FY09
Gross Margin	34.8%-2.0pp	36.8%-0.0pp	36.8%	N/A
Operating Margin	15.9%+8.6pp	7.3%-14.5pp	21.8%	N/A
Net Margin	-0.7%+12.4pp	-13.2%-26.8pp	13.6%	N/A
Return on Equity	-1.3%+18.4pp	-19.8%-53.3pp	33.5%-6.6pp	40.2%
Return on Assets	-0.7%+11.9pp	-12.6%-33.2pp	20.6%	N/A
Current Ratio	1.85-3.5	5.33+2.1	3.19	N/A
Debt-to-Equity	0.05+0.0	0.04-0.0	0.06	N/A
FCF Margin	-7.1%-19.5pp	12.4%-9.1pp	21.4%	N/A

Metric	Q3'13	Q2'13	Q1'13	Q4'12	Q3'12	Q2'12	Q1'12	Q4'11
Gross Margin	28.0%-4.7pp	32.7%-3.1pp	35.8%+2.4pp	33.4%-0.8pp	34.2%-2.7pp	36.9%+1.9pp	35.0%-0.0pp	35.0%
Operating Margin	-8.8%-11.5pp	2.7%+3.5pp	-0.9%-6.3pp	5.4%-16.6pp	22.0%+1.9pp	20.2%+9.4pp	10.8%-4.6pp	15.3%
Net Margin	-5.0%-7.1pp	2.1%+16.6pp	-14.5%-2.8pp	-11.7%-21.5pp	9.8%+6.1pp	3.7%+18.4pp	-14.8%-44.7pp	29.9%
Return on Equity	-1.9%-2.7pp	0.8%+5.2pp	-4.5%+0.5pp	-5.0%-10.8pp	5.9%+4.1pp	1.7%+6.1pp	-4.4%-16.9pp	12.5%
Return on Assets	-1.1%-1.5pp	0.4%+2.8pp	-2.4%+0.3pp	-2.7%-6.1pp	3.4%+2.4pp	1.0%+3.7pp	-2.7%-10.7pp	8.0%
Current Ratio	1.61-0.1	1.73-0.1	1.840.0	1.85-0.1	1.99-0.1	2.11+0.0	2.08-3.3	5.33
Debt-to-Equity	0.050.0	0.05-0.0	0.09+0.0	0.050.0	0.06-0.0	0.10+0.1	0.00-0.0	0.04
FCF Margin	8.9%+22.3pp	-13.4%+4.8pp	-18.2%+57.7pp	-75.8%-87.4pp	11.5%-9.7pp	21.2%+14.2pp	6.9%-0.7pp	7.6%

Similar Companies

Blockchain Loyal BBLC

$6.6M

Puget Technologies Inc PUGE

$949K

Alternaturals ANAS

$938K

Bluefire Equipme BLFR

$1.3M

American Graphit AGIN

$1.3M

Frequently Asked Questions

What is Tanke Biosciences Corp's annual revenue?

Tanke Biosciences Corp (TNBI) reported $28.6M in total revenue for fiscal year 2012. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Tanke Biosciences Corp's revenue growing?

Tanke Biosciences Corp (TNBI) revenue grew by 19.8% year-over-year, from $23.8M to $28.6M in fiscal year 2012.

Is Tanke Biosciences Corp profitable?

No, Tanke Biosciences Corp (TNBI) reported a net income of -$210K in fiscal year 2012, with a net profit margin of -0.7%.

What is Tanke Biosciences Corp's EBITDA?

Tanke Biosciences Corp (TNBI) had EBITDA of $5.2M in fiscal year 2012, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Tanke Biosciences Corp have?

As of fiscal year 2012, Tanke Biosciences Corp (TNBI) had $6.2M in cash and equivalents against $793K in long-term debt.

What is Tanke Biosciences Corp's gross margin?

Tanke Biosciences Corp (TNBI) had a gross margin of 34.8% in fiscal year 2012, indicating the percentage of revenue retained after direct costs of goods sold.

What is Tanke Biosciences Corp's operating margin?

Tanke Biosciences Corp (TNBI) had an operating margin of 15.9% in fiscal year 2012, reflecting the profitability of core business operations before interest and taxes.

What is Tanke Biosciences Corp's net profit margin?

Tanke Biosciences Corp (TNBI) had a net profit margin of -0.7% in fiscal year 2012, representing the share of revenue converted into profit after all expenses.

What is Tanke Biosciences Corp's return on equity (ROE)?

Tanke Biosciences Corp (TNBI) has a return on equity of -1.3% for fiscal year 2012, measuring how efficiently the company generates profit from shareholder equity.

What is Tanke Biosciences Corp's free cash flow?

Tanke Biosciences Corp (TNBI) generated -$2.0M in free cash flow during fiscal year 2012. This represents a -169.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tanke Biosciences Corp's operating cash flow?

Tanke Biosciences Corp (TNBI) generated -$1.2M in operating cash flow during fiscal year 2012, representing cash generated from core business activities.

What are Tanke Biosciences Corp's total assets?

Tanke Biosciences Corp (TNBI) had $28.8M in total assets as of fiscal year 2012, including both current and long-term assets.

What are Tanke Biosciences Corp's capital expenditures?

Tanke Biosciences Corp (TNBI) invested $856K in capital expenditures during fiscal year 2012, funding long-term assets and infrastructure.

How much does Tanke Biosciences Corp spend on research and development?

Tanke Biosciences Corp (TNBI) invested $291K in research and development during fiscal year 2012.

How many shares does Tanke Biosciences Corp have outstanding?

Tanke Biosciences Corp (TNBI) had 13M shares outstanding as of fiscal year 2012.

What is Tanke Biosciences Corp's current ratio?

Tanke Biosciences Corp (TNBI) had a current ratio of 1.85 as of fiscal year 2012, which is generally considered healthy.

What is Tanke Biosciences Corp's debt-to-equity ratio?

Tanke Biosciences Corp (TNBI) had a debt-to-equity ratio of 0.05 as of fiscal year 2012, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tanke Biosciences Corp's return on assets (ROA)?

Tanke Biosciences Corp (TNBI) had a return on assets of -0.7% for fiscal year 2012, measuring how efficiently the company uses its assets to generate profit.

What is Tanke Biosciences Corp's cash runway?

Based on fiscal year 2012 data, Tanke Biosciences Corp (TNBI) had $6.2M in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 63 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tanke Biosciences Corp's Altman Z-Score?

Tanke Biosciences Corp (TNBI) has an Altman Z-Score of 2.12, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Tanke Biosciences Corp's Piotroski F-Score?

Tanke Biosciences Corp (TNBI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tanke Biosciences Corp's earnings high quality?

Tanke Biosciences Corp (TNBI) has an earnings quality ratio of 5.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Tanke Biosciences Corp cover its interest payments?

Tanke Biosciences Corp (TNBI) has an interest coverage ratio of 3.1x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Tanke Biosciences Corp?

Tanke Biosciences Corp (TNBI) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.